The High court today approved the use of Avastin to treat patients with wet age-related macular degeneration. I have used Avastin for over 10 years to treat my private patients as there is good evidence that it works just as well as the officially approved drugs. This will save the NHS £500m a year.
There have been controlled clinical trials and a huge amount of real world data to show that Avastin is just as effective at treating leakage into the retina from wet macular degeneration and other conditions as Lucentis and Eylea but at a fraction of the cost.
The Royal College of Ophthalmologists have promoted its use for several years and it great news that there is now a legal backing to its use.